Who
Polly A. Murphy
Director
Company insider
Files Form 4 as: Director, Atea Pharmaceuticals; Director, Celcuity.
In numbers
- Trades disclosed
- 46
- Buys
- 4
- Sells
- 0
- Bought
- $253K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 3 Nov 2020
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,048 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,048 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,048 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CELC Celcuityoption or derivative · Biotechnology | SEC FORM 4 Code G | —14,048 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CELC CelcuityBiotechnology | SEC FORM 4 Code A | —1,530 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CELC CelcuityBiotechnology | SEC FORM 4 Code A | —1,530 at $0.00 | filing |
| 18 May 2026filed 21 May 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K6,100 at $4.17 | filing |
| 18 May 2026filed 21 May 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K6,100 at $4.17 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,200 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.